Aevi Genomic Medicine (NASDAQ:GNMX) Stock Price Up 15.4%

Share on StockTwits

Aevi Genomic Medicine Inc (NASDAQ:GNMX)’s share price traded up 15.4% on Wednesday . The stock traded as high as $0.14 and last traded at $0.15, 63,069 shares changed hands during mid-day trading. A decline of 87% from the average session volume of 480,368 shares. The stock had previously closed at $0.13.

Separately, ValuEngine lowered shares of Aevi Genomic Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st.

The company has a fifty day moving average price of $0.13 and a 200 day moving average price of $0.17. The stock has a market cap of $8.01 million, a PE ratio of -0.30 and a beta of 0.67.

A hedge fund recently raised its stake in Aevi Genomic Medicine stock. Vanguard Group Inc. raised its stake in Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 82.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,252,050 shares of the biotechnology company’s stock after purchasing an additional 566,497 shares during the quarter. Vanguard Group Inc. owned 1.93% of Aevi Genomic Medicine worth $201,000 at the end of the most recent quarter. 8.39% of the stock is owned by hedge funds and other institutional investors.

Aevi Genomic Medicine Company Profile (NASDAQ:GNMX)

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Further Reading: What sectors are represented in the FTSE 100 index?

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.